Elevation Oncology, Inc. provided program updates and upcoming milestones on January 13, 2025, for its differentiated antibody-drug conjugate (ADC) programs. For EO-3021, dosing has been initiated in the Phase 1 clinical trial cohorts evaluating combinations with ramucirumab or dostarlimab in advanced gastric/gastroesophageal junction (GEJ) cancer.
Initial data from these combination cohorts are expected in the fourth quarter of 2025 or the first quarter of 2026. Additionally, the company plans to report additional monotherapy data from the dose escalation and expansion cohorts of the ongoing Phase 1 clinical trial in the first half of 2025.
Regarding EO-1022, the HER3 ADC, Elevation Oncology plans to present preclinical data in the first half of 2025 and file an Investigational New Drug (IND) application in 2026. The company reiterated its financial guidance, expecting its cash, cash equivalents, and marketable securities as of September 30, 2024, to fund operations into 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.